Our analysis revealed that BAP1-mutant (MUT) CCA cell lines were more sensitive (P < .05) to a range of small molecules that include compounds with activity on PI3K pathway: SANT-2 (SMO antagonist), ABT-737 (inhibitor of Bcl-(X)L, Bcl-2, and Bcl-W), LY294002 (PI3Kα/β/δ inhibitor), PIK-93 (PI3Kα/γ inhibitor), SB203580 (p38 MAPK inhibitor), and SB590885 (BRAF inhibitor). This evidence concerns the gene BAP1 and cholangiocarcinoma.